Format

Send to

Choose Destination
Am J Kidney Dis. 2014 Dec;64(6):836-7. doi: 10.1053/j.ajkd.2014.09.006. Epub 2014 Oct 31.

GFR decline as an end point in trials of CKD: a viewpoint from the FDA.

Author information

1
Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland. Electronic address: Aliza.Thompson@fda.hhs.gov.
2
Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
PMID:
25446026
DOI:
10.1053/j.ajkd.2014.09.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center